Amneal Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson ’s Disease

IPX203 could offer people living with Parkinson’s disease a longer duration of symptom control with less frequent dosing compared to IR CD/LD treatment The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of June 30,...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news